Albinism B-BCVA improves in early school years

Article

Albinos experience an improvement in binocular best-corrected visual acuity (B-BCVA).

Albinos experience an improvement in binocular best-corrected visual acuity (B-BCVA), according to an investigation in the Journal of Paediatric Ophthalmology and Strabismus.

The study, headed by Dr Johanna M. Dijkstal, Department of Ophthalmology, University of Minnesota, Minneapolis, Minnesota, USA, involved the investigation of B-BCVA in albino patients. The information recorded included type of albinism, B-BCVA, glasses wear, iris pigment, macular transparency grade and presence or absence of an annular reflex and melanin in the macular. Each patient was visited between the ages of 5.5 and 9 years (Visit A) and 9.5 and 14 years (Visit B) with a gap of at least 2.5 years between visits.

Visit A revealed a mean B-BCVA of 20/84 and Visit B demonstrated a mean B-BCVA of 20/61, meaning B-BCVA improved by 80%. There was no strong correlation between improvement in B-BCVA and glasses wear, iris grade, macular grade, macular melanin, and annular reflex.

However, from Visit A and Visit the team discovered a moderate correlation between B-BCVA and iris grade. The study showed that B-BCVA frequently improves in albinism in the early school years. It is said to be linked to changes in nystagmus, use of precise null point, developmental maturation, and ocular characteristics.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.